Research and Markets: DRG Insights: Alzheimers Disease

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130222:nBw225193a DUBLIN--(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/nsth6h/drg_insights) has announced the addition of Decision Resources, Inc's new report "DRG Insights: Alzheimers Disease" to their offering. DRG Insights takes the most relevant information and insights from across our portfolio for BioPharma and Med-Tech products and delivers the insight heavy perspective that you need to generate better ideas and deliver more successful campaigns and initiatives. Patients with osteoporosis and osteopenia are at increased risk of suffering fractures. These fractures place a considerable burden on public health systems, and significant unmet need remains in the osteoporosis market for therapies that are safer and more efficacious, particularly in reducing the risk of nonvertebral fractures (e.g., hip fractures). The launch of several key new therapies, coupled with changes in treatment guidelines and in physician prescribing behavior, will lead to important market changes over the 2011-2021 forecast period. As the global population agesparticularly as the baby boomer generation begins to turn 65the Alzheimer's disease (AD) population will grow rapidly. Despite the large patient pool, however, only four compounds are approved for the treatment of AD, all symptomatic ones with only modest efficacy of limited duration. Of critical need are disease-modifying therapies (DMTs) that will slow the progression of the disease (for patients early in the disease course) and improved symptomatic therapies (for patients later in the disease course or for those who may not be candidates for treatment with a DMT). We forecast the launch of two potential DMTs in the next ten years, resulting in a dramatic expansion of the AD market. The availability of improved diagnostics, particularly amyloid imaging agents, will lead to earlier diagnosis and facilitate increased uptake of expensive potential DMTs. Key Topics Covered: Executive Summary Current Market Landscape Etiology & Pathophysiology Staging/Patient Segmentation Select Drug Targets Growth Drivers & Constraints Key Metrics Population Dynamics Market Landscape Current Therapies, Treatment Algorithms Country Specific Decision Trees Comparison of Key Agents Expert Insight on Prescribing Trends Importance of Drug Attributes in Prescribing Decisions Pricing & Reimbursement Factors Influencing Pharmacy Director Tier Placement Decisions Accessibility and Cost Hurdles Reimbursement Environment Unmet NeedsEmerging Therapies Near-term Outlook Long-term Outlook Important Endpoints in Prescribing Decisions Timelines 2010 and 2010 sales and Market Share For more information visit http://www.researchandmarkets.com/research/nsth6h/drg_insights Source: Decision Resources, Inc Research and Markets Laura Wood, Senior Manager. press@researchandmarkets.com U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Healthcare and Medical Devices, Pharmaceuticals Copyright Business Wire 2013